// App-Quantinova.ai

TPS176 : AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC).

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Kim N. Chi

  • David Olmos

  • Heather H. Cheng

  • Neeraj Agarwal

  • Julie N Graff

  • Shahneen Kaur Sandhu

  • Vinny Hayreh

  • Angela Lopez-Gitlitz

  • Peter St. John Francis

  • Gerhardt Attard

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Vancouver Prostate Centre, Vancouver, BC, Canada

  • CNIO - Spanish National Cancer Research Center, Madrid, Spain

  • University of Washington, Seattle, WA

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Knight Cancer Institute, Portland, OR

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Oncology, Los Angeles, CA

  • Medication, Inc., San Francisco, CA

  • The Institute of Cancer Research & The Royal Marsden, London, Spain

Locations

  • United States

  • Canada

  • Spain

  • Australia

  • United Kingdom

Companies

  • Medivation, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Hormone receptor

Drug/Treatment

  • CB-7598

  • Prednisone

  • Niraparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT04497844

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved